A case for CD38 targeted therapy in multi-refractory immune thrombocytopenia

作者
Shahzeem Bhayani,Joshua I. Siner,Morey A. Blinder,Kristen Marie Sanfilippo,Andrew L. Young
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 6602-6602 被引量:1
标识
DOI:10.1182/blood-2025-6602
摘要

Abstract Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody-mediated platelet destruction and bleeding complications. While up to two thirds of patients respond to initial therapy with steroids and/or intravenous immunoglobulin, the remainder of adults develop refractory disease—defined by persistent thrombocytopenia and bleeding. Subsequent lines of therapy include rituximab, thrombopoietin receptor agonists (TPO-RAs), immunosuppressants, and splenectomy. Often these patients face persistent, life-threatening bleeding and more effective therapies are needed. These autoantibodies that are inappropriately produced in B lymphocytes. Many therapies, such as steroids and rituximab, directly target these B cells to mediate their therapeutic effect. About 60% of rituximab treated patients will experience a platelet count response after therapy. Rituximab is an anti-CD20 monoclonal antibody; CD20 is expressed during most stages of B-cell differentiation, from pre-B cells to early plasmablasts. Interestingly, mature plasma cells lose CD20 and secrete large quantities of antibodies. Given this, we hypothesize that patients who do not respond to rituximab may have a more mature plasma cell population secreting antibodies and do not express CD20. These plasma cells highly express CD38, which, fortunately, can be targeted therapeutically. Based on this rationale, we present a case of a critically ill patient with multi-refractory ITP that achieved a durable platelet response and clinical recovery after treatment with a daratumumab—a monoclonal antibody targeting CD38. This 62-year-old man with a remote history of Hodgkin and diffuse large B-cell lymphoma presented with new-onset thrombocytopenia (platelet nadir 1,000/μL) and severe mucocutaneous bleeding. Evaluation of nutritional, infectious, hepatic, malignant and primary bone marrow causes was unrevealing—establishing the diagnosis of primary ITP. Initial treatment with high-dose dexamethasone and IVIG was ineffective. He subsequently received rituximab, eltrombopag and avatrombopag. After seven weeks of persistent, severe thrombocytopenia, he underwent splenectomy, which resulted in a brief, short-lived platelet recovery (peak 29,000/uL). During weeks 8–14, he was treated with romiplostim, a second steroid pulse, mycophenolate, cyclophosphamide, and cyclosporine without response. During this time he was repeatedly hospitalized with severe bleeding managed with platelet transfusions. At week 17, we initiated off-label treatment with daratumumab (anti-CD38 monoclonal antibody) combined with fostamatinib and danazol. Within five days his platelet count returned to normal. Danazol and fostamatinib were discontinued. He completed 12 weekly doses of daratumumab and has remained in stable remission with platelet counts >300,000/μL, now 14 months post-diagnosis. This case highlights both the challenges of managing multi-refractory ITP and the potential of plasma cell directed therapy for this disease. The standard therapies for ITP largely target B cells but fail to eliminate long-lived plasma cells—likely underappreciated producers of pathogenic autoantibodies. In this case, CD38, expressed on plasma cells, was targeted using daratumumab, which induces cell death via multiple mechanisms including complement activation and phagocytosis. Already there is a growing body of literature suggesting that plasma cell directed therapy may have efficacy in other autoimmune hematologic disorders including autoimmune hemolytic anemia, post-transplant cytopenias and refractory ITP. This was the motivation for the Scandinavian DART study. While this study is ongoing, we present this case to highlight that daratumumab can be associated with a rapid platelet recovery in multi-refractory ITP, was safe and well tolerated with fostamatinib and danazol, and produced a durable response after a finite treatment course (12 weekly doses). In conclusion, for patients with prolonged, severe ITP unresponsive to conventional treatments, daratumumab offers a rational, mechanism-based intervention. Our case contributes to growing evidence supporting anti-CD38 immunotherapy in ITP and underscores the need for clinical trials to more broadly evaluate other plasma cell directed therapies for the treatment of ITP.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
幽默鹭洋发布了新的文献求助10
1秒前
文献全拿下完成签到,获得积分10
1秒前
zdw完成签到,获得积分10
1秒前
yangyang发布了新的文献求助10
2秒前
小蘑菇的应助被易拉冠采纳,获得10
2秒前
完美芯发布了新的文献求助30
2秒前
2秒前
木华完成签到,获得积分10
3秒前
张张发布了新的文献求助10
3秒前
4秒前
5秒前
李健的应助被lzx采纳,获得10
5秒前
5秒前
5秒前
小臭哞完成签到 ,获得积分10
6秒前
6秒前
小心完成签到 ,获得积分10
6秒前
圆圆完成签到,获得积分10
6秒前
7秒前
maT发布了新的文献求助10
8秒前
LeonPan完成签到,获得积分10
8秒前
268111gao完成签到,获得积分10
9秒前
幽默鹭洋完成签到,获得积分20
9秒前
9秒前
海岛发布了新的文献求助10
10秒前
XPDrake发布了新的文献求助10
10秒前
酷炫夜白完成签到,获得积分10
11秒前
淡淡的溪灵完成签到,获得积分10
13秒前
烟花的应助被雄壮的小妞采纳,获得10
13秒前
14秒前
yu完成签到 ,获得积分10
14秒前
懒得起名发布了新的文献求助10
14秒前
贪玩芝发布了新的文献求助10
15秒前
领导范儿的应助被man采纳,获得10
15秒前
16秒前
达落完成签到,获得积分10
16秒前
几何完成签到,获得积分10
16秒前
Caspian关注了科研通微信公众号
16秒前
科研学术完成签到,获得积分0
17秒前
桐桐的应助被ai采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178582
求助须知:如何正确求助?哪些是违规求助? 9569391
关于积分的说明 21804062
捐赠科研通 7773535
什么是DOI,文献DOI怎么找? 3432871
关于科研通互助平台的介绍 2556860
邀请新用户注册赠送积分活动 2478451